Cite
HARVARD Citation
Kaseb, A. et al. (2022). Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial. Lancet gastroenterology and hepatology. pp. 208-218. [Online].